Litcius/Paper detail

Development of de-novo coronavirus 3-chymotrypsin-like protease (3CLpro) inhibitors since COVID-19 outbreak: A strategy to tackle challenges of persistent virus infection

Lei Tian, Taotao Qiang, Xiuding Yang, Gao Yue, Xiaopei Zhai, Kairui Kang, Cong Du, Qi Lü, Hong Gao, Dezhu Zhang, Xiaolin Xie, Chengyuan Liang

2023European Journal of Medicinal Chemistry16 citationsDOIOpen Access PDF

Topics & Concepts

PeptidomimeticVirologyProteaseCoronavirus disease 2019 (COVID-19)Drug developmentOutbreakCoronavirusChemistryAntiviral drugSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Computational biologyPharmacologyVirusDrugBiologyEnzymeMedicineBiochemistryInfectious disease (medical specialty)DiseasePeptidePathologyProtein Degradation and InhibitorsPeptidase Inhibition and AnalysisUbiquitin and proteasome pathways
Development of de-novo coronavirus 3-chymotrypsin-like protease (3CLpro) inhibitors since COVID-19 outbreak: A strategy to tackle challenges of persistent virus infection | Litcius